- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Catherine Diefenbach Discusses Reducing Toxicity When Treating Lymphoma
Pairing low doses of chemotherapy with newer, targeted drugs can help prevent high toxicity, said Catherine Diefenbach, MD, director of clinical lymphoma at the NYU Langone Perlmutter Cancer Center.
Pairing low doses of chemotherapy with newer, targeted drugs can help prevent high toxicity, said Catherine Diefenbach, MD, director of clinical lymphoma at the NYU Langone Perlmutter Cancer Center.
Transcript
What is the importance of reducing toxicity in the treatment of lymphoma? How does this affect patients’ overall health in addition to their quality of life?
So, I think in general it’s really important to use the new drugs that we are discovering that are targeted and to combine them intelligently with standard chemotherapy. Because we know that intensive chemotherapy regimens, while very effective in the first line, for patients who have short response or refractory disease are generally not effective in later lines, unless you go to really high doses. And most patients don’t tolerate this well, especially if they’re older, or they have significant toxicity.
So, trying to take a chemotherapy at lower doses and combine it with targeted strategies or immunotherapy is a way to both circumvent the high toxicity of cytotoxic chemotherapy and also rely on tumor biology to be smarter rather than more aggressive about targeting lymphoma.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
